Why do leukemia patients need to take the drug Sorafenib?

Sorafenib is a multi-target tyrosine kinase inhibitor originally used to treat hepatocellular carcinoma, renal cancer, and thyroid cancer. But in recent years, studies have found that it also shows potential efficacy in certain types of leukemia, especially in patients with acute myeloid leukemia (AML) who carry FLT3 mutations. FLT3 is one of the common gene mutations in leukemia cells. This mutation will promote abnormal proliferation of leukemia cells, leading to rapid disease progression and poor prognosis.

For FLT3-ITD mutation-positive AML patients, sorafenib can inhibit the FLT3 signaling pathway, thereby reducing the division and survival of leukemia cells and improving the treatment response rate after chemotherapy or hematopoietic stem cell transplantation. Some studies have also shown that sorafenib combined with standard chemotherapy or used as maintenance treatment after transplantation can help delay disease recurrence and improve disease-free survival (DFS) and overall survival (OS).

In addition to FLT3positive patients, sorafenib is also used for the treatment of refractory or relapsed AML, especially in patients who are ineffective or intolerant to conventional treatments. It can be used as single-agent maintenance therapy or as part of a combination regimen to slow disease progression and relieve leukemia-related symptoms. In some cases, sorafenib even helps patients regain the chance of transplantation and prolong survival.

Overall, the main reason for leukemia patients to take sorafenib is its ability to target FLT3 mutations or provide a new treatment option after other treatments have failed. Although it is not a standard drug for all leukemia patients, sorafenib has become an effective adjuvant treatment tool in certain genetic backgrounds or treatment stages. Doctors will evaluate whether sorafenib is suitable for use based on the patient's specific molecular test results and condition to achieve personalized and precise treatment.

Reference materials:https://www.drugs.com/